Research Groups

Mechanisms of Carcinogenesis - Molecular Mechanisms and Biomarkers Group

Previous Publications - All publications 2016-2012

1. Tissot C., Villar S., Olivier M., Couraud S. (2016) [Free circulating DNA as a tool for lung cancer patients management] Revue de Pneumologie Clinique; 72(1):61-71. PMID: 26190335

2. Tissot C., Toffart A. C., Villar S., Souquet P. J., Merle P., Moro-Sibilot D., Perol M., Zavadil J., Brambilla C., Olivier M., Couraud S. (2015) Circulating free DNA concentration is an independent prognostic biomarker in lung cancer European Respiratory Journal; 46(6):1773-80. PMID: 26493785

3. Castells X., Karanovic S., Ardin M., Tomic K., Xylinas E., Durand G., Villar S., Forey N., Le Calvez-Kelm F., Voegele C., Karlovic K., Misic M., Dittrich D., Dolgalev I., McKay J., Shariat S. F., Sidorenko V. S., Fernandes A., Heguy A., Dickman K. G., Olivier M., Grollman A. P., Jelakovic B., Zavadil J. (2015) Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid Cancer Epidemiology, Biomarkers and Prevention; 24(12):1873-81. PMID: 26383547

4. Wild C., Brennan P., Plummer M., Bray F., Straif K., Zavadil J. (2015) Cancer risk: role of chance overstated Science; 347(6223):728. PMID: 25656657

5. Vaca-Paniagua F., Oliver J., Nogueira da Costa A., Merle P., McKay J., Herceg Z., Holmila R. (2015) Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing ; 7(3):353-362. PMID: 26077425

6. Vaca-Paniagua F., Alvarez-Gomez R.M., Maldonado-Martinez H.A., Perez-Plasencia C., Fragoso-Ontiveros V., Lasa-Gonsebatt F., Herrera L.A., Cantu D., Bargallo-Rocha E., Mohar A., Durand G., Forey N., Voegele C., Vallee M., Le Calvez-Kelm F., McKay J., Ardin M., Villar S., Zavadil J., Olivier M. (2015) Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues ; 10(5):e0126762. PMID: 25961742

7. Traore F., Gormally E., Villar S., Friesen M. D., Groopman J. D., Vernet G., Diallo S., Hainaut P., Maiga M. Y. (2015) Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali BMC Infectious Diseases; 180. PMID: 25886382

8. Tissot C., Toffart A.C., Villar S., Souquet P.J., Merle P., Moro-Sibilot D., Perol M., Zavadil J., Brambilla C., Olivier M., Couraud S. (2015) Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy. Journal of Clinical Oncology; 33(15):Suppl. Abstract: 110.

9. Ose J., Fortner R.T., Schock H., Peeters P.H., Onland-Moret N.C., Bueno-de-Mesquita H.B., Weiderpass E., Gram I.T., Overvad K., Tjonneland A., Dossus L., Fournier A., Baglietto L., Trichopoulou A., Benetou V., Trichopoulos D., Boeing H., Masala G., Krogh V., Matiello A., Tumino R., Popovic M., Obon-Santacana M., Larranaga N., Ardanaz E., Sanchez M., Menendez V., Chirlaque M., Travis R.C., Khaw K., Brandstedt J., Idahl A., Lundin E., Rinaldi S., Kuhn E., Romieu I., Gunter M.J., Merritt M.A., Riboli E., Kaaks R. (2015) Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort British Journal of Cancer; 112(1):162-166. PMID: 25349976

10. Ose J., Fortner R.T., Rinaldi S., Schock H., Overvad K., Tjonneland A., Hansen L., Dossus L., Fournier A., Baglietto L., Romieu I., Kuhn E., Boeing H., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Masala G., Sieri S., Tumino R., Sacerdote C., Mattiello A., Ramon Quiros J., Obon-Santacana M., Larranaga N., Chirlaque M.D., Sanchez M.J., Barricarte A., Peeters P.H., Bueno-de-Mesquita H.B., Onland-Moret N.C., Brandstedt J., Lundin E., Idahl A., Weiderpass E., Gram I.T., Lund E., Kaw K.T., Travis R.C., Merritt M.A., Gunther M.J., Riboli E., Kaaks R. (2015) Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition International Journal of Cancer; 136(2):399-410.

11. Mariga A., Zavadil J., Ginsberg S.D., Chao M.V. (2015) Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function ; 75(2):173-192. PMID: 25059794

12. Krais A.M., Muhlbauer K.R., Kucab J.E., Chinbuah H., Cornelius M.G., Wei Q.X., Hollstein M., Phillips D.H., Arlt V.M., Schmeiser H.H. (2015) Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts Toxicology in Vitro; 29(1):34-43. PMID: 25230394

13. Jelakovic B., Castells X., Tomic K., Ardin M., Karanovic S., Zavadil J. (2015) Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid Int. J Cancer; 136(12):2967-2972.

14. Zavadil J. (2014) Multi-'Omics Approaches to Environmental Cancer Risk Factors: A Spotlight on Exposure to Aristolochic Acid and Its Biological Consequences Environmental and Molecular Mutagenesis; S23 (S15).

15. Scelo G., Riazalhosseini Y., Greger L., Letourneau L., Gonzalez-Porta M., Wozniak M.B., Bourgey M., Harnden P., Egevad L., Jackson S.M., Karimzadeh M., Arseneault M., Lepage P., How-Kit A., Daunay A., Renault V., Blanche H., Tubacher E., Sehmoun J., Viksna J., Celms E., Opmanis M., Zarins A., Vasudev N.S., Seywright M., Abedi-Ardekani B., Carreira C., Selby P.J., Cartledge J.J., Byrnes G., Zavadil J., Su J., Holcatova I., Brisuda A., Zaridze D., Moukeria A., Foretova L., Navratilova M., Mates D., Jinga V., Artemov A., Nedoluzhko A., Mazur A., Rastorguev S., Boulygina E., Heath S., Gut M., Bihoreau M.T., Lechner D., Foglio M., Gut I.G., Skryabin K., Prokhortchouk E., Cambon-Thomsen A., Rung J., Bourque G., Brennan P., Tost J., Banks R.E., Brazma A., Lathrop G.M. (2014) Variation in genomic landscape of clear cell renal cell carcinoma across Europe Nat Commun; 5135.

16. Sagne C., Marcel V., Bota M., Martel-Planche G., Nobrega A., Palmero E.I., Perriaud L., Boniol M., Vagner S., Cox D.G., Chan C.S., Mergny J.L., Olivier M., Ashton-Prolla P., Hall J., Hainaut P., Achatz M.I. (2014) Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures Carcinogenesis; 35(4):807-815.

17. Olivier M., Weninger A., Ardin M., Huskova H., Castells X., Vallee M.P., McKay J., Nedelko T., Muehlbauer K.R., Marusawa H., Alexander J., Hazelwood L., Byrnes G., Hollstein M., Zavadil J. (2014) Modelling mutational landscapes of human cancers in vitro Scientific Reports; 4482.

18. Mimoso C., Lee D.D., Zavadil J., Tomic-Canic M., Blumenberg M. (2014) Analysis and meta-analysis of transcriptional profiling in human epidermis ; 61-97.

19. Ma X., Rousseau V., Sun H., Lantuejoul S., Filipits M., Pirker R., Popper H., Mendiboure J., Vataire A.L., Le Chevalier T., Soria J.C., Brambilla E., Dunant A., Hainaut P. (2014) Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer ; 8(3):555-564.

20. Karanovic S., Tomic K., Dittrich D., Borovecki F., Zavadil J., Vukovic-Lela I., Karlovic K., Knezevic M., Jelakovic B. (2014) Endemic (Balkan) nephropathy is aristolochic acid nephropathy Prilozi. Contributions; 35(1):43-46.

21. Izetti P., Hautefeuille A., Abujamra A.L., de Farias C.B., Giacomazzi J., Alemar B., Lenz G., Roesler R., Schwartsmann G., Osvaldt A.B., Hainaut P., Ashton-Prolla P. (2014) PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines Investigational New Drugs; 32(5):783-794.

22. Giacomazzi J., Graudenz M.S., Osorio C.A., Koehler-Santos P., Palmero E.I., Zagonel-Oliveira M., Michelli R.A., Neto C.S., Fernandes G.C., Achatz M.I., Martel-Planche G., Soares F.A., Caleffi M., Goldim J.R., Hainaut P., Camey S.A., Ashton-Prolla P. (2014) Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil PloS One; 9(6):e99893.

23. Dai Y., Cros M.P., Pontoizeau C., Elena-Hermann B., Bonn G.K., Hainaut P. (2014) Downregulation of transcription factor E4F1 in hepatocarcinoma cells: HBV-dependent effects on autophagy, proliferation and metabolism Carcinogenesis; 35(3):635-650.

24. Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanche H., Girard N., Tredaniel J., Guilleminault L., Gervais R., Prim N., Vincent M., Margery J., Larive S., Foucher P., Duvert B., Vallee M., Le Calvez-Kelm F., McKay J., Missy P., Morin F., Zalcman G., Olivier M., Souquet P.J. (2014) Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 Clinical Cancer Research; 20(17):4613-4624.

25. Cortot A.B., Younes M., Martel-Planche G., Guibert B., Isaac S., Souquet P.J., Commo F., Girard P., Fouret P., Brambilla E., Hainaut P., Soria J.C. (2014) Mutation of TP53 and Alteration of p14(arf) Expression in EGFR- and KRAS-mutated lung adenocarcinomas. Clinical Lung Cancer; 15(2):124-130.

26. SEQC/MAQC-III Consortium (2014) A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium Nature Biotechnology; 32(9):903-914.

27. Sighoko D., Kamate B., Traore C., Malle B., Coulibaly B., Karidiatou A., Diallo C., Bah E., McCormack V., Muwonge R., Bourgeois D., Gormally E., Curado M.P., Bayo S., Hainaut P. (2013) Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive life ; 22(5):828-835.

28. Shepherd F.A., Domerg C., Hainaut P., Janne P.A., Pignon J.P., Graziano S., Douillard J.Y., Brambilla E., Le Chevalier T., Seymour L., Bourredjem A., Le Teuff G., Pirker R., Filipits M., Rosell R., Kratzke R., Bandarchi B., Ma X., Capelletti M., Soria J.C., Tsao M.S. (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy Journal of Clinical Oncology; 31(17):2173-2181.

29. Sagne C., Marcel V., Amadou A., Hainaut P., Olivier M., Hall J. (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects ; e492.

30. Ortiz-Cuaran S., Villar S., Gouas D., Ferro G., Plymoth A., Khuhaprema T., Kalalak A., Sangrajrang S., Friesen M.D., Groopman J.D., Hainaut P. (2013) Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand Cancer Letters; 331(1):46-51.

31. Ortiz-Cuaran S., Cox D., Villar S., Friesen M.D., Durand G., Chabrier A., Khuhaprema T., Sangrajrang S., Ognjanovic S., Groopman J.D., Hainaut P., Le Calvez-Kelm F. (2013) Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma ; 52(10):912-919.

32. Olivier M. (2013) TP53 somatic mutations: prognostic and predictive value in human cancers ; 127-146.

33. Lu X., Wontakal S.N., Kavi H., Kim B.J., Guzzardo P.M., Emelyanov A.V., Xu N., Hannon G.J., Zavadil J., Fyodorov D.V., Skoultchi A.I. (2013) Drosophila H1 regulates the genetic activity of heterochromatin by recruitment of Su(var)3-9 Science; 340(6128):78-81.

34. Langerod A., Olivier M., Borresen-Dale A.L. (2013) ; 147-165.

35. Hollstein M., Moriya M., Grollman A.P., Olivier M. (2013) Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid ; 753(1):41-49.

36. Hainaut P., Olivier M., Wiman K.G. (2013) P53 in the Clinics ; .

37. Hainaut P. (2013) TP53: coordinator of the processes that underlie the hallmarks of cancer ; 1-23.

38. Hafsi H., Santos-Silva D., Courtois-Cox S., Hainaut P. (2013) Effects of Delta40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53 ; 134.

39. Fye H.K., Wright-Drakesmith C., Kramer H.B., Camey S., Nogueira da Costa A., Jeng A., Bah A., Kirk G.D., Sharif M.I., Ladep N.G., Okeke E., Hainaut P., Taylor-Robinson S.D., Kessler B.M., Mendy M.E. (2013) Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations ; 8(7):e68381.

40. Dichtel-Danjoy M.L., Ma D., Dourlen P., Chatelain G., Napoletano F., Robin M., Corbet M., Levet C., Hafsi H., Hainaut P., Ryoo H.D., Bourdon J.C., Mollereau B. (2013) Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation ; 20(1):108-116.

41. Villar S., Ortiz-Cuaran S., Abedi-Ardekani B., Gouas D., Nogueira da Costa A., Plymoth A., Khuhaprema T., Kalalak A., Sangrajrang S., Friesen M.D., Groopman J.D., Hainaut P. (2012) Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis PloS One; 7(6):e37707.

42. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., Hainaut P., Marrero J.A., Beretta L. (2012) Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology; 55(2):483-490.

43. Scoccianti C., Vesin A., Martel G., Olivier M., Brambilla E., Timsit J.F., Tavecchio L., Brambilla C., Field J.K., Hainaut P. (2012) Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort European Respiratory Journal; 40(1):177-184.

44. Ognjanovic S., Martel G., Manivel C., Olivier M., Langer E., Hainaut P. (2012) Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma ; 492086.

45. Hainaut P., Plymoth A. (2012) Cancer as a metabolic disease Current Opinion in Oncology; 24(1):56-57.

46. Gouas D.A., Villar S., Ortiz-Cuaran S., Legros P., Ferro G., Kirk G.D., Lesi O.A., Mendy M., Bah E., Friesen M.D., Groopman J., Chemin I., Hainaut P. (2012) TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia Carcinogenesis; 33(6):1219-1224.

47. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., Haupt S., de Lange J., Yip D., Goydos J., Haigh J.J., Haupt Y., Larue L., Jochemsen A., Shi H., Moriceau G., Lo R.S., Ghanem G., Shackleton M., Bernal F., Marine J.C. (2012) MDM4 is a key therapeutic target in cutaneous melanoma Nature Medicine; 18(8):1239-1247.

48. Fernandez-Cuesta L., Oakman C., Falagan-Lotsch P., Smoth K.S., Quinaux E., Buyse M., Dolci M.S., Azambuja E.D., Hainaut P., Dell'orto P., Larsimont D., Francis P.A., Crown J., Piccart-Gebhart M., Viale G., Leo A.D., Olivier M. (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Breast Cancer Research; 14(3):R70.

49. de Fraipont F., Levallet G., Creveuil C., Bergot E., Beau-Faller M., Mounawar M., Richard N., Antoine M., Rouquette I., Favrot M.C., Debieuvre D., Braun D., Westeel V., Quoix E., Brambilla E., Hainaut P., Moro-Sibilot D., Morin F., Milleron B., Zalcman G. (2012) An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial Clinical Cancer Research; 18(10):2976-2986.

50. Blandino G., Deppert W., Hainaut P., Levine A., Lozano G., Olivier M., Rotter V., Wiman K., Oren M. (2012) Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop Cell Death and Differentiation; 19(1):180-183.

51. Abedi-Ardekani B., Dar N.A., Mir M.M., Zargar S.A., Lone M.M., Martel-Planche G., Villar S., Mounawar M., Saidi F., Malekzadeh R., Hainaut P. (2012) Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia ; 602.